icon
موقع حكومي رسمي تابع لحكومة المملكة العربية السعودية
icon السبت 13 جمادى الأولى 1448هـ
نسخة تجريبية
icon
روابط المواقع الالكترونية الرسمية السعودية تنتهي بـ gov.sa

جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa

icon
المواقع الرسمية الآمنة تستخدم HTTPS

تحقق من أن الموقع يستخدم بروتوكول HTTPS

icon

مسجل لدى هيئة الحكومة الرقمية برقم :

20250831619
اقتراحات

قائمة الدراسات السريرية المسجلة على الادوية

عرض 221 - 230 من 518
عنوان الدراسة داعم الدراسة حالة الدراسة دواء الدراسة مرحلة الدراسة رقم بروتوكول الدراسة موقع الدراسة
An open-Label, multicenter, expanded access study of Everolimus in Patients with advanced Nerouendocrine tumors. Novartis Completed Everolimus 3b CRAD001K24133 King Faisal Specialist Hospital and Research Center (Riyadh)
An Open-lable, Randomized, Multi center, Phase III Study to Compare the Saftey and Efficacy of TKI258 Versus Sorafenib in Patients with Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor Therapies" Novartis Completed TKI258 / Sorafenib 3 CTKI258A2302 King Faisal Specialist Hospital and Research Center (Riyadh)
Extending molecular responeses with Nilotinib in newly diagnosed chronic myeloid leukemia (CML) patients in chronic phase (ENESTxtnd) Novartis Completed Nilotinib 3b CAMN107E2401 King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Hospital and Oncology Center (Jeddah)
A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION) AstraZeneca Ongoing Tezepelumab 3 D5180C00018 King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Riyadh)
Comparison of the Efficacy and Safety for different regimen of Venous Thromboembolism pharmacoprophylaxis among Severely Burn Patients: A Multicenter, Randomized Controlled Trial KAIMRC Ongoing HEPARIN SODIUM, ENOXAPARIN SODIUM 4 RC18/400/R King Abdulaziz Medical City NG (Riyadh)
Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters in patients with asthma SANOFI Ongoing DUPILUMAB 4 LPS15834 King Fahad Medical City (Riyadh)
Psoriasis Study of Health Outcomes (PSoHO) – an International Observational Study of 3-Year Health Outcomes in the Biologic Treatment of Moderate-to-Severe Plaque Psoriasis Eli Lilly Ongoing Any biologic therapy (including biosimilars) available on the market and prescribe to patients within routine care 4 1F-MC-B007 Hira Hospital (Makkah)
Global cross-sectional burden-of-illness study in adolescent and adult patients with atopic dermatitis (MEASURE-AD) Abbvie Ongoing Drug choice as per treating physician which is not limited per the protocol 4 H19-940 Hira Hospital (Makkah), Security Force Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS Sanofi Ongoing DUPILUMAB 4 OBS15990 King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam)
"A Multinational, Prospective, Observational Study of theEffectiveness, Healthcare Resource Utilization and Costsin Patients with Rheumatoid Arthritis ReceivingBaricitinib, Targeted Synthetic or BiologicDisease-Modifying Therapies" Eli Lilly Ongoing Baricitinib 4 I4V-MCB009 Specialized Medical Center (Riyadh), Dr. Sulaiman Al-Habib Medical Group Takhassusi (Riyadh)